Researchers have found that LLM-driven bug finding is not a drop-in replacement for mature static analysis pipelines. Studies comparing AI coding agents to human developers show that while AI can be ...

The approval coincides with a new policy requiring first-year students to live on campus beginning this fall, unless they live within 30 miles of campus or are facing specific circumstances.

Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of 80% in the 2026 Antimicrobial ...

Singapore, March 10: Graduates from Singapore Management University continue to secure good employment outcomes despite a more cautious hiring climate, with more than nine in ten securing employment ...

A nationally representative Education Week survey found that 56 percent of educators believe that “off-task behavior on laptops, tablets, or desktops is a major source of distraction that cuts into ...

Existing research on AI for mental health has many limitations. A new study shows this. Yet research is vital, so we must recalibrate. An AI Insider scoop.

Graduates from Singapore Management University continue to secure good employment outcomes despite a more cautious hiring climate, with more than nine in ten securing employment within six months of ...

Satellos Bioscience Inc. (" Satellos " or the " Company "), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced interim ...

China’s updated Catalogue of Encouraged Service Imports (2026) identifies priority sectors to import high-quality international services.

Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled ...

RIT has launched a new decade-long strategic framework that will guide the university’s priorities, investments, inspiration, and aspirations through 2035.

GSK and Alfasigma have signed a licensing agreement granting Alfasigma worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational IBAT inhibitor for the ...